Funding for this research was provided by:
Engineering and Physical Sciences Research Council (EP/L015803/1)
Small Business Innovation Research (1950994)
Received: 8 March 2021
Accepted: 21 June 2021
First Online: 28 August 2021
: All procedures performed involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: James Morrill declares that he receives grant support from the Engineering and Physical Sciences Research Council under the program grant EP/L015803/1. Dr. Andrew Ambrosy declares that he is supported by a Mentored Patient-Oriented Research Career Development Award (K23HL150159) through the National Heart, Lung and Blood institute and he has received relevant research support through grants to his institution from Amarin Pharma, Inc., Abbott, and Novartis, including modest travel reimb from Novartis. Dr. Marat Fudim declares that he is supported by The National Heart, Lung, and Blood Institute grant K23HL151744; The American Heart Association grant 20IPA35310955; Mario Family Award; Duke Chair’s Award; Translating Duke Health Award; Bayer; and BTG Specialty Pharmaceuticals. He further receives consulting fees from AstraZeneca, AxonTherapies, CVRx, Daxor, Edwards LifeSciences, Galvani, NXT Biomedical, Zoll, Viscardia. Dr. Sumanth Swaminathan and Dr. Botros Toro both declare that they receive partial funding from the National Science Foundation Small Business Innovation Research Grant (no. 1950994) and that they are both shareholders of Vironix Health, Inc. Dr. Nicholas Wysham declares that he is a consultant for and shareholder of Vironix Health. Dr. Klajdi Qirko, Dr. Ted Smith, and Dr. Jacob Kelly declare that they have no conflicts of interest.